Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.67 |
| ▸ | DRD2 | P14416 | 9/20 | 0.49 |
| ▸ | HTR2A | P28223 | 7/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8546588 | 0.99 | HTR1A (0.66) | HTR1ASLC6A4DRD2HTR2ACYP2C9 | |
| SCHEMBL6017099 | 0.94 | HTR1A (0.60) | HTR1ASLC6A4DRD2HTR2AMEN1 | |
| Hydrochloric Acid SCHEMBL8543603 | 0.93 | HTR1A (0.59) | HTR1ASLC6A4DRD2HTR2AMEN1 | |
| SCHEMBL6017126 | 0.91 | HTR1A (0.66) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL6017215 | 0.91 | HTR1A (0.66) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL6017467 | 0.91 | HTR1A (0.66) | HTR1ASLC6A4DRD2HTR2ACYP2C9 | |
| Hydrochloric Acid SCHEMBL8548723 | 0.90 | HTR1A (0.65) | HTR1ASLC6A4DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL8544273 | 0.90 | HTR1A (0.65) | HTR1ASLC6A4DRD2HTR2ACYP2C9 | |
| Hydrochloric Acid SCHEMBL8550841 | 0.90 | HTR1A (0.65) | HTR1ASLC6A4DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL6017134 | 0.88 | HTR1A (0.56) | HTR1ASLC6A4DRD2HTR2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660079-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | disclosed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018569-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| EP-0660832-B1 | SEROTONIN RECEPTOR AGENTS | MERRELL PHARMA INC (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5436246-A | Compounds for treatment of anxiety, depression, migraine, stroke, angina and hypertension | MERRELL DOW PHARMACEUTICALS INC. | 1995-07-25 | — | — | US | disclosed |
| EP-0660832-A1 | SEROTONIN RECEPTOR AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-07-05 | — | — | EP | disclosed |
| WO-1994006789-A1 | SEROTONIN RECEPTOR AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | TPH2, TPH1, HTR2A | HTR1A 4/4885SLC6A4 27/4885DRD2 359/4885 |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | TPH2, TPH1, HTR2A | HTR1A 6/4885SLC6A4 34/4885DRD2 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.